Quick Answer
Matinas BioPharma Holdings, Inc. reported Diluted EPS of $2.00 per share (loss) for fiscal year 2025.
Matinas BioPharma Holdings, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.00 | +59.8% |
| 2024 | -$4.98 | +5.7% |
| 2023 | -$5.28 | -5180.0% |
| 2022 | -$0.10 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.40 | +52.9% | +61.2% |
| June 30, 2025 | -$1.03 | +10.4% | -212.1% |
| March 31, 2025 | -$0.33 | +75.4% | +61.2% |
| September 30, 2024 | -$0.85 | +38.8% | +26.1% |
| June 30, 2024 | -$1.15 | -3733.3% | +14.2% |
| March 31, 2024 | -$1.34 | -4366.7% | +3.6% |
| September 30, 2023 | -$1.39 | -4533.3% | -4533.3% |
| June 30, 2023 | -$0.03 | +0.0% | +0.0% |
- Matinas BioPharma Holdings, Inc. showed an increase of +59.8% in Diluted EPS compared to the prior fiscal year.
- Over the 2022–2025 period, Matinas BioPharma Holdings, Inc.’s diluted eps has declined by 1900.0% (from $0.10 per share (loss) to $2.00 per share (loss)).
- The most recent figure is from Matinas BioPharma Holdings, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: